Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus
Top Cited Papers
Open Access
- 2 August 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 10, 1781
- https://doi.org/10.3389/fmicb.2019.01781
Abstract
Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.This publication has 131 references indexed in Scilit:
- Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine CandidatemBio, 2013
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirusProceedings of the National Academy of Sciences of the United States of America, 2013
- Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in HumansmBio, 2012
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative ImmunogenicityPLOS ONE, 2012
- An animal model that reflects human disease: the common marmoset (Callithrix jacchus)Current Opinion in Virology, 2012
- Clinical Applications of DNA Vaccines: Current ProgressClinical Infectious Diseases, 2011
- Rationalizing the development of live attenuated virus vaccinesNature Biotechnology, 2010
- Memory CD4 T cells: generation, reactivation and re‐assignmentImmunology, 2010
- Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal ImmunizationJournal of Virology, 2008
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004